135 related articles for article (PubMed ID: 1341722)
1. Clinical management of prolactinomas: a ten-year experience.
Merola B; Colao A; Panza N; Caruso E; Spaziante R; Schettini G; de Divitiis E; Pacilio G; Lombardi G
Med Oncol Tumor Pharmacother; 1992; 9(2):93-9. PubMed ID: 1341722
[TBL] [Abstract][Full Text] [Related]
2. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
Colao A; Merola B; Sarnacchiaro F; Di Sarno A; Landi ML; Marzullo P; Cerbone G; Ferone D; Lombardi G
Horm Res; 1995; 44(5):222-8. PubMed ID: 8582715
[TBL] [Abstract][Full Text] [Related]
3. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
4. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.
Passos VQ; Souza JJ; Musolino NR; Bronstein MD
J Clin Endocrinol Metab; 2002 Aug; 87(8):3578-82. PubMed ID: 12161478
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
Chattopadhyay A; Bhansali A; Masoodi SR
Pituitary; 2005; 8(2):147-54. PubMed ID: 16379032
[TBL] [Abstract][Full Text] [Related]
7. Combined treatment of invasive giant prolactinomas.
Yu C; Wu Z; Gong J
Pituitary; 2005; 8(1):61-5. PubMed ID: 16411070
[TBL] [Abstract][Full Text] [Related]
8. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
[TBL] [Abstract][Full Text] [Related]
9. Giant Prolactinomas: Outcomes of Multimodal Treatments for 42 Cases with Long-Term Follow-Up.
Lv L; Hu Y; Yin S; Zhou P; Yang Y; Ma W; Zhang S; Wang X; Jiang S
Exp Clin Endocrinol Diabetes; 2019 May; 127(5):295-302. PubMed ID: 29940665
[TBL] [Abstract][Full Text] [Related]
10. [Dopamine-agonist resistant prolactinomas: diagnosis and management].
Musolino NR; Passos VQ
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):641-50. PubMed ID: 16444347
[TBL] [Abstract][Full Text] [Related]
11. [Alteration of prolactin secretion after transsphenoidal adenomectomy for prolactinomas].
Yokoyama M
No To Shinkei; 1990 Aug; 42(8):773-9. PubMed ID: 2223270
[TBL] [Abstract][Full Text] [Related]
12. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
13. Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches.
Fideleff HL; Boquete HR; Sequera A; Suárez M; Sobrado P; Giaccio A
J Pediatr Endocrinol Metab; 2000 Mar; 13(3):261-7. PubMed ID: 10714751
[TBL] [Abstract][Full Text] [Related]
14. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
15. Treatment of macroprolactinomas at Auckland Hospital 1975-91.
Wallace EA; Holdaway IM
N Z Med J; 1995 Feb; 108(994):50-2. PubMed ID: 7885646
[TBL] [Abstract][Full Text] [Related]
16. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
Montini M; Pagani G; Gianola D; Pagani MD; Salmoiraghi M; Ferrari L; Lancranjan I
J Clin Endocrinol Metab; 1986 Jul; 63(1):266-8. PubMed ID: 3711262
[TBL] [Abstract][Full Text] [Related]
17. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and long-term tolerability of the slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia.
Merola B; Colao A; Caruso E; Sarnacchiaro F; Lancranjan I; Lombardi G; Schettini G
J Endocrinol Invest; 1992 Mar; 15(3):173-6. PubMed ID: 1624676
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Microscopic and Endoscopic Transsphenoidal Surgery Versus Medical Therapy in the Management of Microprolactinoma in the United States.
Jethwa PR; Patel TD; Hajart AF; Eloy JA; Couldwell WT; Liu JK
World Neurosurg; 2016 Mar; 87():65-76. PubMed ID: 26548828
[TBL] [Abstract][Full Text] [Related]
20. Management of resistant prolactinomas.
Olafsdottir A; Schlechte J
Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
